Edition:
United Kingdom

McKesson Corp (MCK.N)

MCK.N on New York Stock Exchange

146.74USD
19 Jun 2018
Change (% chg)

$0.70 (+0.48%)
Prev Close
$146.04
Open
$145.00
Day's High
$147.09
Day's Low
$144.38
Volume
362,493
Avg. Vol
436,870
52-wk High
$178.86
52-wk Low
$134.28

Select another date:

Mon, Apr 30 2018

BRIEF-McKesson Board Of Directors Elects Brad Lerman As New Independent Director

* MCKESSON BOARD OF DIRECTORS ELECTS BRAD LERMAN AS NEW INDEPENDENT DIRECTOR

BRIEF-McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook

* MCKESSON LAUNCHES MULTI-YEAR STRATEGIC GROWTH INITIATIVE; REAFFIRMS FISCAL 2018 OUTLOOK AND PROVIDES PRELIMINARY FISCAL 2019 OUTLOOK

BRIEF-Polarityte Announces Appointment Of Mckesson’S Willie Bogan To Board Of Directors

* POLARITYTE ANNOUNCES APPOINTMENT OF MCKESSON’S WILLIE BOGAN TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Two-Part Note Offering

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART NOTE OFFERING OF UP TO EUR 750 MILLION - SEC FILING Source text : (http://bit.ly/2H0ogwC) Further company coverage:

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Notes Due 2028

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL NOTES DUE 2028 OFFERING OF UP TO $600 MILLION - SEC FILING Source text : (http://bit.ly/2G22iIb) Further company coverage:

BRIEF-Mckesson Files Preliminary Prospectus Supplement Related To Potential Offering Of Notes

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL OFFERING OF NOTES DUE 2020 - SEC FILING Source text - http://bit.ly/2FUEDJW Further company coverage:

McKesson says drug prices competitive but not volatile like 2017

U.S. drug wholesaler McKesson Corp said prices of generic drugs were still competitive, but not as volatile as in 2017 when prices fell sharply, which should help the company as it benefits from a major tie-up with Walmart.

UPDATE 3-McKesson says drug prices competitive but not volatile like 2017

* Books tax benefit of $370 mln in 3rd quarter (Adds company commentary on generic drug prices, background, analyst quotes; updates stock prices)

CORRECTED-UPDATE 1-Drug distributor McKesson's quarterly profit beats estimates

Feb 1 McKesson Corp posted a better-than-expected quarterly profit, as the biggest U.S. drug distributor continues to benefit from its tie-up with Walmart .

BRIEF-McKesson Reports Q3 Adjusted Earnings Per Share $3.41

* Q3 GAAP EARNINGS PER SHARE $4.32 FROM CONTINUING OPERATIONS

Select another date: